InsidersTradesSigma
Discover the detailed record of transactions filed by Haft Nicholas, Director. Director active across 1 companies, notably Finch Therapeutics Group, Inc.. Cumulatively, 2 reports have been published. Total volume traded: €1.2m. The latest transaction was filed on 20 December 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
2 of 2 declarations
Nicholas Haft is a Director at Finch Therapeutics Group, Inc. In this role, he participates in the governance of the company and strategic decision-making. His expertise in biotechnology is valuable for Finch Therapeutics, which develops innovative therapies.